Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 28, 2022; 28(36): 5280-5299
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5280
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5280
Ref. | EtOH feeding model | Platform, route of administration (targeting strategy) | Cargo, paradigm (prevention or treatment) | Physical characterization | Empty particle control | Results | Mechanisms | |||
Size (nm) | Charge (mV) | EE% | In vitro | In vivo | ||||||
Liposomes | ||||||||||
Ponnappa et al[24], 2005 | Rat chronic (8-10 wk), males | Liposomes, i.v. (passive) | S-ODN, prevention | N/P | N/P | 10%-14% | Yes | ↓ Liver injury (ALT) | - | ↓ Serum and liver TNFα |
Rodriguez et al[28], 2019 | Mouse acute-on-chronic, males | Fusogenic liposomes, i.p. (passive) | Rolipram, treatment | N/P | N/P | N/P | No | ↓ Liver injury (ALT and AST); ↓ Steatosis; ↓ Oxidative stress; ↓ ER Stress; ↓ Liver cell apoptosis | - | ↑ Hepatic cAMP; ↑ Sod1 and Sod2; ↓ ATF3, Atf4, CHOP, and Gadd34; ↑ Bcl-xl; ↓ Caspase activation |
Zhao et al[32], 2016 | Mouse chronic (8 wk), males | Liposomes, i.v. (passive) | Puerarin, Prevention | Approximately 182 | Approximately -29.4 | 93.6% ± 1.7% | Yes | ↓ Liver injury (ALT and AST) | - | - |
Wu et al[35], 2019 | Mouse EtOH binge (3 wk), males | Liposomes, i.p. or oral (passive) | Astaxanthin, prevention | 225.0 ± 58.3 | N/P | 98% | Yes | ↓ Liver injury (ALT and AST); ↓ Liver fibrosis | - | - |
Kumar et al[36], 2019 | Rat chronic (4 wk via 2 × daily gavage), males | Liposomes, oral (passive) | Silymarin, treatment | Approximately 146.9 | Approximately -47.4 | 50.50% | No | ↓ Liver injury (ALT and AST); ↑ Liver function (albumin); ↓ Oxidative stress; ↓ Liver inflammation | ↓ Apoptosis in Chang cells | ↑ SOD, GSH, catalase; ↓ TBARS; ↓ IL-6, MPO, nitrite |
Yu et al[37], 2021 | Mouse acute-on-chronic, males | Liposomes, oral (passive) | Saikosaponin D, prevention | 61.66 ± 3.89 | -37.18 ± 2.89 | 92.28% ± 0.84% | Yes | ↓ Liver injury (ALT and AST); ↓ Steatosis; ↓ Oxidative stress; ↓ Liver inflammation | - | ↓ MDA; ↑ GPx, SOD; ↓ Liver TNFα |
Jain et al[38], 2013 | Rat chronic (8 wk), males and females | Liposomes, oral (passive) | Mangiferin, prevention | 980 ± 230 | N/P | N/A | No | ↓ Oxidative stress | - | ↓ MDA; ↑ SOD, GSH, catalase |
Exosomes | ||||||||||
Gu et al[50], 2021 | Mouse acute-on-chronic, males | Exosomes, from LGG, oral (passive) | Endogenous cargo, treatment | 75 ± 12.7 | N/P | N/A | N/A | ↓ Liver injury (ALT and AST); ↓ Steatosis | ↓ TNFα, Il-6, IL-1β, Mcp1 in RAW264.7 cells; ↑ AhR activity in gut leukocytes; ↑ ZO-1, occludin, claudin-1, Nrf2 in Caco-2 cells | ↓ Tnf and Il-1β; ↑ Cyp1a1, IL-22, Reg3b, Reg3g; ↓ Hepatic bacteria; ↓ Liver endotoxin; ↑ Nrf2 |
Zhuang et al[57], 2015 | Mouse acute-on-chronic, males | Exosomes from ginger, oral (passive) | Endogenous cargo, prevention | Approximately 340.4 | Approximately -27.2 | N/P | N/A | ↓ Liver injury (ALT and AST); ↓ Steatosis | - | ↑ Nrf2 activation |
Polymeric nanoparticles | ||||||||||
Nag et al[64], 2020 | Mouse chronic drinking water (16 wk), males | Poly(lactic-co-glycolic acid) nanoparticles, i.p. (passive) | Tannic acid/ vitamin e, treatment | 127.5 ± 1.6 | -21.2 ± 0.39 | Tannic acid: 69.7% ± 2.6%; Vitamin E: 63.7% ± 3.2% | No | ↓ Liver injury (ALT, AST, ALP); ↓ Steatosis; ↓ Liver fibrosis; ↓ Oxidative stress; ↓ Liver cell apoptosis; ↓ Liver inflammation; ↑ Cell survival | - | ↑ HDL ↓ LDL; ↓ ROS; ↑ Catalase, GPx, Nrf2; ↓ Bax, bad, cytochrome C, caspase activation; ↑ Bcl2; ↓ TFGβ, IL-6, TNFα, IL-1β, iNOS, COX2; ↓ EGF, EGFR, AKT, PI3K, and mTOR |
Natarajan et al[68], 2019 | Mouse chronic (4 wk), males | Poly l-lysine-polyethylene glycol copolymer nanoparticles, i.p. (passive) | Superoxide dismutase, treatment | Approximately 44 | N/P | N/P | No | ↓ Steatosis; ↓ Liver inflammation | ↑ SOD1 and ↓ DCF in E47 Hepatoma cells | ↓ SREBP1; ↑ ADH1; ↓ Cd68, Ccl2, Mmp12, MCP1, and CCR2; ↑ P-AMPKα |
Gopal et al[73], 2020 | Mouse chronic (4 wk), males | Poly l-lysine-polyethylene glycol copolymer nanoparticles, i.p. (passive) | Superoxide dismutase 1, treatment | Approximately 44 | N/P | N/P | No | ↓ Liver injury (ALT); ↓ Steatosis | - | ↓ Plasma and liver MCP-1; ↑ Pparα, Acox1, and Acot1; ↑ Mt2; ↑ SOD1 activity |
Zhang et al[75], 2022 | Mouse chronic (3 wk) + CCL4, females | Chol-PCX nanoparticles, i.v. (passive) | PCX and anti-miR-155, Treatment | Approximately 70 | Approximately 25 | N/P | No | ↓ Liver injury (ALT); ↓ Liver fibrosis; ↓ Liver inflammation | ↓ LPS-induced miR-155 expression in RAW264.7 cells; ↑ CXCR4 antagonism in U20S cells | ↓ Col1a1, MMPs, TIMPs, HSC activation; ↓ F480+ cells |
Wang et al[76], 2020 | Mouse EtOH binge (4 d), females | Angelica sinensis amphipathic cholesteryl hemisuccinate conjugate nanoparticles, i.v. (passive) | Curcumin, prevention | Approximately 208.4 | Approximately -20 | 54.7%-86.1% | Yes | ↓ Liver injury (ALT and AST); ↓ Oxidative stress | - | ↑ GSH; ↓ ROS (DHE and MDA) |
Bacteria and viruses | ||||||||||
Hendrikx et al[83], 2019 | Mouse acute-on-chronic, male and females | L. reuteri, oral (intestine-targeted) | IL-22, prevention | N/A | N/A | N/A | Yes (regular L. reuteri) | ↓ Liver injury (ALT); ↓ Steatosis (ORO and TG); ↓ Liver inflammation; ↑ Intestinal barrier defense | - | ↓ Cxcl1, Cxcl2; ↑ Small intestine Reg3g; ↓ Hepatic bacteria |
Satishchandran et al[93], 2018 | Mouse chronic (5 wk), females | AAV8, i.v. (active) | pri-MiR122, treatment | N/A | N/A | N/A | Yes (scrambled miRNA) | ↓ Liver injury (ALT); ↓ Steatosis (TG, ORO); ↓ Liver inflammation; ↓ Liver fibrosis (Sirius red) | - | ↓ MCP1, IL-1β; ↓ Col1a1 |
- Citation: Warner JB, Guenthner SC, Hardesty JE, McClain CJ, Warner DR, Kirpich IA. Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease. World J Gastroenterol 2022; 28(36): 5280-5299
- URL: https://www.wjgnet.com/1007-9327/full/v28/i36/5280.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i36.5280